myelodysplastic syndromes (MDS) | Aplastic Anemia & MDS International Foundation

myelodysplastic syndromes (MDS)

A Caregiver's Story: MDS Diagnosis Changes their Lives

Person's Name: 
Danielle Sulyma

I know my fiancé well.  Even though he seemed to be healthy and his job kept him active, I knew it had been a long time since he had a medical physical, so I pushed him into an appointment.

Without symptoms, the doctor suggested routine blood work as a part of the physical.  We were surprised that all his counts were low.  The doctor decided to check again in a month, so I made sure that his diet was healthier and that he took vitamins, hoping that would correct any problem.  

Content source: 
Bone Marrow Diseases: 

Is blood transfusion safe during the COVID-19 pandemic?

Josiane Bassil, Elie Rassy, Joseph Kattan
Primary Author: 
Bassil J
Journal Title: 
Future Science OA
Original Publication Date: 
Sep 2020

The rapid spread of the coronavirus disease 2019 (COVID-19) pandemic has challenged healthcare systems to re-organize the management of patients in a short period. The causative pathogen of this pandemic is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), one of seven coronaviruses that can be found in humans. It is a rapidly mutating, enveloped, ssRNA, beta-coronavirus. The initial reports published after the pandemic spread showed a transmissibility rate of 2.2 and possibly low values of dispersion.

Study of Mana 312 (Multi Tumor-Associated Antigen T Cells) in Adults With AML/MDS After HSCT

This is a Phase 1, open-label, non-randomized, single and multiple dose escalation study designed to evaluate the safety and preliminary efficacy (prevention of, or treatment of relapse) of administering Mana 312 to subjects with AML/MDS after allogeneic HSCT. The study will evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of single and multiple doses of Mana 312. Each cycle of administration of Mana 312 will be 28 days.

Martha L. Arellano, MD

Arellano, Martha
Associate Professor, Department of Hematology and Medical Oncology
Emory University

Martha L. Arellano, MD, is an Associate Professor in the Department of Hematology and Medical Oncology at the Emory University School of Medicine where she serves as Associate Director of the Division of Hematology. Board certified in hematology, medical oncology and internal medicine, Dr. Arellano specializes in the treatment of leukemia and